DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Not Applicable

Terminated

Conditions: Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Procedure: Culdocentesis
Procedure: Vaginal Swab
Procedure: Chromopertubation
Procedure: Blood collection
Procedure: Tissue collection

First Posted Date: 2015-05-12

Last Posted Date: 2020-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02441140

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: GS-1101

First Posted Date: 2015-05-08

Last Posted Date: 2017-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02439138

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

Phase 2

Active, not recruiting

Conditions: Langerhans Cell Histiocytosis

Interventions: Drug: Clofarabine

First Posted Date: 2015-04-24

Last Posted Date: 2024-10-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02425904

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States

and more 11 locations

Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer

Not Applicable

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: Indocyanine green (ICG)
Device: FluoSCOPE

First Posted Date: 2015-04-22

Last Posted Date: 2018-05-16

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02423148

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Phase 1

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib
Drug: Sorafenib
Drug: Radium-223

First Posted Date: 2015-04-02

Last Posted Date: 2020-03-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02406521

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ixazomib
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2015-03-27

Last Posted Date: 2020-09-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT02400437

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Completed

Conditions: Myelodysplastic Syndromes (MDS)

First Posted Date: 2015-03-17

Last Posted Date: 2023-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 290

Registration Number: NCT02390414

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Elotuzumab
Drug: Bortezomib
Drug: Dexamethasone
Procedure: Stem Cell Mobilization

First Posted Date: 2015-03-02

Last Posted Date: 2024-09-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02375555

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 4 locations

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma
Hodgkin Lymphoma
Peripheral T-Cell Lymphoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2015-02-13

Last Posted Date: 2023-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 82

Registration Number: NCT02362997

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

Patient-Centered Care for the Older Adult With Hematologic Malignancy

Not Applicable

Completed

Conditions: Hematologic Malignancy

Interventions: Other: Baseline Geriatric Screening/Assessment
Other: Geriatrician Co-Management

First Posted Date: 2015-02-10

Last Posted Date: 2022-07-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 160

Registration Number: NCT02359838

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy